Overview of Treatment Options for the Management of Relapsed/Refractory Multiple Myeloma (R/R MM)

Thomas G. Martin, MD, discussed with his colleagues cytokine release syndrome after treatment with teclistamab for patients with multiple myeloma.

Experts discuss key data updates in real-world newly diagnosed multiple myeloma practices, and how these findings may change the treatment paradigm.

A single dose of motixafortide results in achievement of stem cell collection goal in patients with multiple myeloma.

Experts from Mayo Clinic and The University of Texas MD Anderson Cancer Center discuss results from multiple myeloma trials presented at the 2023 American Society of Clinical Oncology Annual Meeting and how they may apply to clinical practice.

Patients with multiple myeloma and enduring MRD-negativity are able to achieve the deepest responses with ciltacabtagene autoleucel, according to Yi Lin, MD, PhD.

Investigators report that patients with relapsed/refractory myeloma treated with mezigdomide and dexamethasone primarily experienced myelotoxic effects.